GlassScriptPhysician profile
Neil H Wasserman
NPI 1285621250
$2,803.52
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $386 · 2021: $387 · 2022: $336.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $466.92 | 2019-2022 | |
| Pfizer INC. | $374.51 | 2019-2021 | |
| Abbvie INC. | $225.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $165.22 | 2019-2020 | |
| Amarin Pharma, INC. | $162.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $145.37 | 2019-2022 | |
| Novo Nordisk INC | $116.24 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.62 | 2019-2020 | |
| Astellas Pharma US INC | $99.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $90.18 | 2019-2022 | |
| Allergan, INC. | $82.55 | 2019-2020 | |
| Sanofi Pasteur INC. | $79.97 | 2019-2020 | |
| Lilly USA, LLC | $75.46 | 2019 | |
| Abbott Laboratories | $73.29 | 2021-2022 | |
| Amgen INC. | $69.23 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $69.23 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $56.66 | 2019 | |
| Shire North American Group INC | $49.03 | 2019 | |
| Hikma Pharmaceuticals USA | $46.98 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $44.19 | 2019-2022 | |
| Eisai INC. | $35.45 | 2021-2022 | |
| Genentech USA, INC. | $25.94 | 2019 | |
| Collegium Pharmaceutical, INC. | $25.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.60 | 2022 | |
| Amryt Pharma Holdings LTD | $22.27 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.24 | 2019 | |
| Corcept Therapeutics | $16.26 | 2019 | |
| Daiichi Sankyo INC. | $15.03 | 2019 | |
| Bausch Health US, LLC | $14.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.